Who owns DEERFIELD PRIVATE DESIGN FUND IV, L.P.?

No ownership or control links for DEERFIELD PRIVATE DESIGN FUND IV, L.P. are resolved in the current sources yet — view the network graph to expand, or pull the cited JSON dossier.

What is DEERFIELD PRIVATE DESIGN FUND IV, L.P.'s risk level?

WhiteIntel flags DEERFIELD PRIVATE DESIGN FUND IV, L.P. as low risk. Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership.

Where does DEERFIELD PRIVATE DESIGN FUND IV, L.P. appear across sources?

DEERFIELD PRIVATE DESIGN FUND IV, L.P. is resolved across GLEIF into one cited cluster in the WhiteIntel corporate-ownership graph, with a source on every claim.

SearchLIVE · CORPUS

/ Dossier

■

DEERFIELD PRIVATE DESIGN FUND IV, L.P.

Name: DEERFIELD PRIVATE DESIGN FUND IV, L.P. — ownership dossier
Creator: WhiteIntel
License: https://creativecommons.org/licenses/by/4.0/
Keywords: corporate ownership, beneficial ownership, UBO, corporate intelligence, OSINT, corporate registry, DEERFIELD PRIVATE DESIGN FUND IV, L.P., Company, US

Low

Company·US·sec:0001680307

JSON / MCP View network

DEERFIELD PRIVATE DESIGN FUND IV, L.P. is a Company registered in US resolved across 1 source in the WhiteIntel corporate-ownership graph.

ALSO APPEARS IN · GLEIF

DEERFIELD PRIVATE DESIGN FUND IV, L.P.GLEIF · lei:549300QJOA5QI17WBG46

The same real-world entity, resolved across sources.

Ownership & control

Owners / controllers

None in current sources.

Holdings / subsidiaries

■
Larimar Therapeutics, Inc.
other · via SEC EDGAR
■
Larimar Therapeutics, Inc.
director · via SEC EDGAR
■
Larimar Therapeutics, Inc.
tenpercentowner · via SEC EDGAR
■
Nuvalent, Inc.
tenpercentowner · via SEC EDGAR
■
Nuvalent, Inc.
director · via SEC EDGAR
■
Nuvalent, Inc.
other · via SEC EDGAR
■
ARS Pharmaceuticals, Inc.
tenpercentowner · via SEC EDGAR
■
AdaptHealth Corp.
tenpercentowner · via SEC EDGAR
■
AdaptHealth Corp.
other · via SEC EDGAR
■
ARS Pharmaceuticals, Inc.
tenpercentownerother · via SEC EDGAR
■
Nuvalent, Inc.
tenpercentownerother · via SEC EDGAR
■
ARS Pharmaceuticals, Inc.
director · via SEC EDGAR
■
Larimar Therapeutics, Inc.
tenpercentownerother · via SEC EDGAR
■
Mirum Pharmaceuticals, Inc.
tenpercentownerother · via SEC EDGAR
■
Oncology Institute, Inc.
tenpercentownerother · via SEC EDGAR
■
Singular Genomics Systems, Inc.
tenpercentownerother · via SEC EDGAR
■
Edgewise Therapeutics, Inc.
tenpercentownerother · via SEC EDGAR
■
Annexon, Inc.
tenpercentownerother · via SEC EDGAR
■
Nkarta, Inc.
tenpercentownerother · via SEC EDGAR
■
Oncology Institute, Inc.
director · via SEC EDGAR
■
Schrodinger, Inc.
tenpercentownerother · via SEC EDGAR
■
Revolution Medicines, Inc.
tenpercentownerother · via SEC EDGAR
■
Cabaletta Bio, Inc.
tenpercentownerother · via SEC EDGAR
■
Korro Bio, Inc.
tenpercentownerother · via SEC EDGAR
■
AdaptHealth Corp.
director · via SEC EDGAR
■
AdaptHealth Corp.
tenpercentownerother · via SEC EDGAR
■
ARVINAS, INC.
tenpercentownerother · via SEC EDGAR
■
Protara Therapeutics, Inc.
directorother · via SEC EDGAR

DEERFIELD PRIVATE DESIGN FUND IV, L.P.

/01Ownership & control

Ownership & control